Trends in personalized therapies in oncology: The (venture) capitalist's perspective

Journal of Personalized Medicine

Volumn 2, Issue 1, 2012, Pages 15-34

  Fleck, Roman ^a   Bach, Daniel ^a  

^a Index Ventures   (Switzerland)

Author keywords

Collaboration BioPharma Academia; Global industry trends; Oncology drug development; Translational research

Indexed keywords

ABIRATERONE; ARSENIC TRIOXIDE; BUSULFAN; CAPECITABINE; CETUXIMAB; CRIZOTINIB; DASATINIB; DENILEUKIN DIFTITOX; ERLOTINIB; GEFITINIB; IMATINIB; IPILIMUMAB; IRINOTECAN; LAPATINIB; MERCAPTOPURINE; NILOTINIB; PANITUMUMAB; TAMOXIFEN; TIOGUANINE; TRASTUZUMAB; VANDETANIB; VEMURAFENIB;

ARTICLE; CANCER THERAPY; CLINICAL PRACTICE; DRUG COST; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG MANUFACTURE; GENE SEQUENCE; HUMAN; MOLECULARLY TARGETED THERAPY; ONCOLOGY; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); SIDE EFFECT; TRANSLATIONAL RESEARCH;

EID: 84897931325     PISSN: None     EISSN: 20754426     Source Type: Journal    
DOI: 10.3390/jpm2010015     Document Type: Article

References (31)

1. FDA. Drugs@FDA. Available online: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/(accessed on 7 February 2012).
2. Datamonitor. Market and Product Forecasts: Targeted Cancer Therapies-Trend towards Personalized Medicine Will Lead to Market Fragmentation. 2011. HC00118-008.
3. Stratton, M.R.; Campbell, P.J.; Futreal, P.A. The cancer genome. Nature 2009, 458, 719-724.
4. Hinds, D.A.; Stuve, L.L.; Nilsen, G.B.; Halperin, E.; Eskin, E.; Ballinger, D.G.; Frazer, K.A.; Cox, D.R. Whole-genome patterns of common DNA variation in three human populations. Science 2005, 307, 1072-1079.
5. Medtrack. Medtrack: Biomedical Corporate Intelligence Database. Available online: http://www.medtrack.com/(accessed on 7 February 2012).
6. Thomson Reuters. Thomson Reuters Pharma Database. New York, NY, USA, 2011. Available online: https://www.thomson-pharma.com/(accessed on 7 February 2012).
7. Sawyers, C.L.; Hochhaus, A.; Feldman, E.; Goldman, J.M.; Miller, C.B.; Ottmann, O.G.; Schiffer, C.A.; Talpaz, M.; Guilhot, F.; Deininger, M.W.; et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: Results of a phase II study. Blood 2002, 99, 3530-3539.
8. Kantarjian, H.M.; Cortes, J.; O'Brien, S.; Giles, F.J.; Albitar, M.; Rios, M.B.; Shan, J.; Faderl, S.; Garcia-Manero, G.; Thomas, D.A.; et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002, 99, 3547-3553.
9. Druker, B.J.; Talpaz, M.; Resta, D.J.; Peng, B.; Buchdunger, E.; Ford, J.M.; Lydon, N.B.; Kantarjian, H.; Capdeville, R.; Ohno-Jones, S.; et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 2001, 344, 1031-1037.
10. Hochhaus, A.; O'Brien, S.G.; Guilhot, F.; Druker, B.J.; Branford, S.; Foroni, L.; Goldman, J.M.; Müller, M.C.; Radich, J.P.; Rudoltz, M.; et al. IRIS Investigators. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009, 23, 1054-1061.
11. Simonsson, B.; Gedde-Dahl, T.; Markevärn, B.; Remes, K.; Stentoft, J.; Almqvist, A.; Björeman, M.; Flogegård, M.; Koskenvesa, P.; Lindblom, A.; et al. Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low-or intermediate-risk chronic myeloid leukemia. Blood 2011, 118, 3228-3235.
12. Meng, J.; Dai, B.; Fang, B.; Bekele, B.N.; Bornmann, W.G.; Sun, D.; Peng, Z.; Herbst, R.S.; Papadimitrakopoulou, V.; Minna, J.D.; et al. Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. PLOS One 2010, 5, doi:10.1371/journal.pone.0014124.
13. Novartis. Novartis Oncology Products. Available online: http://www.novartisoncology.com/novartis-oncology-products/(accessed on 7 February 2012).
14. Engelman, J.A.; Jänne, P.A. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin. Cancer Res. 2008, 14, 2895-2899.
15. Linardou, H.; Dahabreh, I.J.; Kanaloupiti, D.; Siannis, F.; Bafaloukos, D.; Kosmidis, P.; Papadimitriou, C.A.; Murray, S. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: A systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 2008, 9, 962-972.
16. Marchant, J. Key Trends in Drug-Diagnostic Co-Development; Business Insight Ltd.: Dallas, TX, USA, 2009.
17. Solit, D.B.; Garraway, L.A.; Pratilas, C.A.; Sawai, A.; Getz, G.; Basso, A.; Ye, Q.; Lobo, J.M.; She, Y.; Osman, I.; et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006, 439, 358-362.
18. Zhang, J.; Yang, P.L.; Gray, N.S. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 2009, 9, 28-39.
19. Tutt, A.; Robson, M.; Garber, J.E.; Domchek, S.; Audeh, M.W.; Weitze, J.N.; Friedlander, M.; Carmichael, J. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J. Clin. Oncol. ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2009, 27(15S), CRA501
20. Audeh, M.W.; Penson, R.T.; Friedlander, M.; Powell, B.; Bell-McGuinn, K.M.; Scott, C.; Weitzel, J.N.; Carmichael, J.; Tutt, A. Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer. J. Clin. Oncol. ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2009, 27 (15S), 5500.
21. Sessa, C.; Guibal, A.; Del Conte, G.; Rüegg, C. Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: Tools or decorations? Nat. Clin. Pract. Oncol. 2008, 5, 378-391.
22. Gorre, M.E.; Mohammed, M.; Ellwood, K.; Hsu, N.; Paquette, R.; Rao, P.N.; Sawyers, C.L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293, 876-880.
23. Bhutia, S.K.; Mallick, S.K.; Maiti, T.K. Tumour escape mechanisms and their therapeutic implications in combination tumour therapy. Cell Biol. Int. 2010, 34, 553-563.
24. Kantarjian, H.; Giles, F.; Wunderle, L.; Bhalla, K.; O'Brien, S.; Wassmann, B.; Tanaka, C.; Manley, P.; Rae, P.; Mietlowski, W.; et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med. 2006, 354, 2542-2551.
25. Carlson, R.H. Ponatinib effective in heavily pretreated CML patients with T3151 mutation. Oncol. Times UK 2011, 8, 17-18.
26. Romond, E.H.; Perez, E.A.; Bryant, J.; Suman, V.J.; Geyer, C.E., Jr.; Davidson, N.E.; Tan-Chiu, E.; Martino, S.; Paik, S.; Kaufman, P.A.; et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 2005, 353, 1673-1684.
27. Nahta, R.; Esteva, F.J. Herceptin: Mechanisms of action and resistance. Cancer Lett. 2006, 232, 123-138.
28. Willett, C.G.; Boucher, Y.; di Tomaso, E.; Duda, D.G.; Munn, L.L.; Tong, R.T.; Chung, D.C.; Sahani, D.V.; Kalva, S.P.; Kozin, S.V.; et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 2004, 10, 145-147.
29. Hodi, F.S.; O'Day, S.J.; McDermott, D.F.; Weber, R.W.; Sosman, J.A.; Haanen, J.B.; Gonzalez, R.; Robert, C.; Schadendorf, D.; Hassel, J.C.; et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363, 711-723.
30. Sussman, L. Matching targeted therapies to tumor's specific gene mutations key to personalized cancer treatment. Eurekalert. Available online: http://www.eurekalert.org/pub_releases/2011-06/uotm-mtt060311.php (accessed on 20 January 2012).
31. Gonzalez-Angulo, A.M.; Hennessy, B.T.; Mills, G.B. Future of personalized medicine in oncology: A systems biology approach. J. Clin. Oncol. 2010, 28, 2777-2783.